Christopher A. Fausel

560 total citations
23 papers, 350 citations indexed

About

Christopher A. Fausel is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Christopher A. Fausel has authored 23 papers receiving a total of 350 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Christopher A. Fausel's work include Acute Myeloid Leukemia Research (6 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Christopher A. Fausel is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Hematopoietic Stem Cell Transplantation (4 papers). Christopher A. Fausel collaborates with scholars based in United States and Jamaica. Christopher A. Fausel's co-authors include Joel Picus, Cynthia S. Johnson, Costantine Albany, Lawrence H. Einhorn, Mary J. Brames, Rafat Abonour, Anne Greist, Mitchell Goldman, Attaya Suvannasankha and Lisa L. Wood and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and The Oncologist.

In The Last Decade

Christopher A. Fausel

23 papers receiving 340 citations

Peers

Countries citing papers authored by Christopher A. Fausel

Since Specialization

Citations

This map shows the geographic impact of Christopher A. Fausel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher A. Fausel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher A. Fausel more than expected).

Fields of papers citing papers by Christopher A. Fausel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher A. Fausel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher A. Fausel. The network helps show where Christopher A. Fausel may publish in the future.

Co-authorship network of co-authors of Christopher A. Fausel

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher A. Fausel. A scholar is included among the top collaborators of Christopher A. Fausel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher A. Fausel. Christopher A. Fausel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma 2024 ·Bone Marrow Transplantation ·(unknown), Suzanne Arinsburg, (unknown), Tomer M. Mark, Christopher A. Fausel, Joseph Bubalo, Gary Milkovich, Erin Moshier, Weijia Fu, Ajai Chari, Joshua Richter	1
2	A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma 2024 ·Frontiers in Oncology ·Ahmed Bilal Khalid, Christos Fountzilas, Heather Burney, Hirva Mamdani, Bryan P. Schneider, Christopher A. Fausel, Susan M. Perkins, Shadia I. Jalal	1
3	Prevalence of the concurrent administration of contraindicated medications in patients with cancer treated with tyrosine kinase inhibitors (TKIs): A pilot study from the IU Simon Comprehensive Cancer Center. 2021 ·Journal of Clinical Oncology ·(unknown), Yan Han, (unknown), Todd C. Skaar, Christopher A. Fausel, Nasser H. Hanna	1
4	Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study 2016 ·Supportive Care in Cancer ·Nabil Adra, Costantine Albany, Mary J. Brames, (unknown), Cynthia S. Johnson, Ziyue Liu, Christopher A. Fausel, T. Breen, Nasser H. Hanna, Ralph J. Hauke, Joel Picus, Lawrence H. Einhorn	8
5	Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology Pharmacy 2016 ·Hospital Pharmacy ·Lisa M. Hess, (unknown), (unknown), (unknown), Christopher A. Fausel, (unknown), (unknown), (unknown), Sinem Perk, Robert W. Klein	7
6	Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study. 2015 ·Journal of Clinical Oncology ·Mary J. Brames, (unknown), Nasser H. Hanna, Christopher A. Fausel, T. Breen, Lawrence H. Einhorn	2
7	Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153. 2014 ·Journal of Clinical Oncology ·Costantine Albany, Nasser H. Hanna, Joel Picus, Ralph J. Hauke, Christopher A. Fausel, Ziyue Liu, Mary J. Brames, Lawrence H. Einhorn	2
8	Comparison of an assumption‐free Bayesian approach with Optimal Sampling Schedule to a maximum a posteriori Approach for Personalizing Cyclophosphamide Dosing 2013 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·José M. Laínez‐Aguirre, Seza Orçun, Joseph F. Pekny, Gintaras V. Reklaitis, Attaya Suvannasankha, Christopher A. Fausel, Elias Anaissie, Gary Blau	8
9	Observations of Second Primary Malignancy in Patients With Multiple Myeloma 2011 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Christopher A. Fausel, Rafat Abonour, Patrick J. Kiel	11
10	Prophylaxis with Sirolimus and Tacrolimus ± Antithymocyte Globulin Reduces the Risk of Acute Graft-versus-Host Disease without an Overall Survival Benefit Following Allogeneic Stem Cell Transplantation 2010 ·Biology of Blood and Marrow Transplantation ·(unknown), Patrick J. Kiel, Iftekhar Kalsekar, Craig Vargo, (unknown), (unknown), Lisa L. Wood, (unknown), Jennifer E. Schwartz, Shivani Srivastava, Rafat Abonour, Michael J. Robertson, Robert P. Nelson, Kenneth Cornetta, Christopher A. Fausel, Sherif S. Farag	27
11	Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia 2010 ·Bone Marrow Transplantation ·R.P. Nelson, Menggang Yu, Jennifer E. Schwartz, Michael J. Robertson, Robert Hromas, Christopher A. Fausel, Gail H. Vance, S. R. Dlouhy, (unknown), Elizabeth Cox, (unknown), Shivani Srivastava, Kent A. Robertson, Paul R. Haut, Sherif S. Farag, Rafat Abonour, Kenneth Cornetta, Larry D. Cripe	14
12	Iron chelation therapy in myelodysplastic syndromes 2010 ·American Journal of Health-System Pharmacy ·Christopher A. Fausel	3
13	Targeted Chronic Myeloid Leukemia Therapy: Seeking a Cure 2007 ·Journal of Managed Care Pharmacy ·Christopher A. Fausel	35
14	Physical compatibility and chemical stability of mycophenolate mofetil during simulated Y-site administration with commonly coadministered drugs 2007 ·American Journal of Health-System Pharmacy ·(unknown), Kevin M. Sowinski, Christopher A. Fausel, Brian R. Overholser	4
15	Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01-21 2007 ·The Oncologist ·Attaya Suvannasankha, Christopher A. Fausel, Beth E. Juliar, Constantin T. Yiannoutsos, William B. Fisher, Rafat Ansari, Lisa L. Wood, (unknown), Larry D. Cripe, Rafat Abonour	36
16	Targeted chronic myeloid leukemia therapy: Seeking a cure 2007 ·American Journal of Health-System Pharmacy ·Christopher A. Fausel	62
17	Novel treatment strategies for chronic myeloid leukemia 2006 ·American Journal of Health-System Pharmacy ·Christopher A. Fausel	2
18	Introduction 2006 ·American Journal of Health-System Pharmacy ·Christopher A. Fausel	1
19	Recurring Chemotherapy‐Associated Alopecia Areata: Case Report and Literature Review 2003 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·(unknown), Christopher A. Fausel	7
20	Central Nervous System Infections Due toStomatococcus mucilaginosusin Immunocompromised Hosts 1998 ·Clinical Infectious Diseases ·Mitchell Goldman, (unknown), Anne Greist, Christopher A. Fausel	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact